By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celsion Corporation 

997 Lenox Drive
Suite 100
Lawrenceville  New Jersey  08648  U.S.A.
Phone: 609-896-9100 Fax: 609-896-2200


Medical Device

Company News
Celsion Corporation (CLSN) And myTomorrows Partner To Introduce Thermodox® Early Access Program In Europe For Patients With Recurrent Chest Wall Breast Cancer 1/20/2015 8:15:14 AM
Celsion Corporation (CLSN) Submits DNA-Based Immunotherapy Clinical Protocol To The FDA As Part Of A First Line Treatment For Ovarian Cancer 1/6/2015 7:40:30 AM
Celsion Corporation (CLSN) Reports Third Quarter 2014 Financial Results 11/11/2014 8:33:22 AM
Celsion Corporation (CLSN) Receives VHP Approval To Initiate OPTIMA Study In Europe 11/5/2014 7:29:42 AM
Celsion Corporation (CLSN) To Hold Third Quarter 2014 Financial Results Conference Call On Tuesday, November 11, 2014 11/4/2014 9:03:51 AM
Celsion Corporation (CLSN) Presents Preclinical Data For Its TheraSilence™ Platform At The miRNA World Conference Workshop On miRNA Delivery 10/29/2014 8:09:48 AM
Celsion Corporation (CLSN) Announces Appointment Of Michael H. Tardugno To Executive Chairman Of The Board Of Directors 10/8/2014 8:21:48 AM
Celsion Corporation (CLSN) Announces The Unexpected Passing Of Max E. Link, Ph.D., Chairman Of The Board 10/8/2014 8:19:01 AM
Celsion Corporation (CLSN) Announces Highlights From Three Presentations Given At The International Liver Cancer Association 2014 Annual Conference 9/8/2014 9:24:34 AM
Celsion Corporation (CLSN) Reports Consolidated Duke University And Celsion's DIGNITY Study Clinical Data On Thermodox® In Recurrent Chest Wall Breast Cancer Published In The International Journal Of Hyperthermia 9/5/2014 10:48:50 AM